Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geraldine R Vink

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Therapeutic Advances in Gastroenterology|September 30, 2020
Model-based evaluation of the cost effectiveness of 3 <i>versus</i> 6 months' adjuvant chemotherapy in high-risk stage II colon cancer patientsGabrielle Jongeneel, Marjolein J E Greuter, Felice N van Erning, et al.
International Journal of Cancer|July 9, 2020
Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life dataPatricia A H Hamers, Marloes A G Elferink, Rebecca K Stellato, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2023
Impact of colorectal cancer screening on survival after metachronous metastasisPatricia A H Hamers, Geraldine R Vink, Marloes A G Elferink, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2024
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 monthsIngrid A Franken, Frederieke H van der Baan, Geraldine R Vink, et al.
International Journal of Cancer|August 20, 2019
Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world dataGabrielle Jongeneel, Thomas Klausch, Felice N van Erning, et al.
Journal of Geriatric Oncology|September 4, 2019
Development of a self-reported version of the G8 screening toolInez Charlotte van Walree, Ariel M Vondeling, Geraldine R Vink, et al.
Journal of Clinical Pathology|October 22, 2021
Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practiceElisabeth M P Steeghs, Geraldine R Vink, Marloes A G Elferink, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 20, 2021
Survival of surgical and non-surgical older patients with non-metastatic colorectal cancer: A population-based study in the NetherlandsEllen van der Vlies, Lisette M Vernooij, Felice N van Erning, et al.
Clinical Colorectal Cancer|April 27, 2022
Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)Patricia A H Hamers, Geraldine R Vink, Marloes A G Elferink, et al.
International Journal of Cancer|January 18, 2021
Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort studyGabrielle Jongeneel, Marjolein J E Greuter, Felice N van Erning, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Therapeutic Advances in Gastroenterology|September 30, 2020
Model-based evaluation of the cost effectiveness of 3 <i>versus</i> 6 months' adjuvant chemotherapy in high-risk stage II colon cancer patientsGabrielle Jongeneel, Marjolein J E Greuter, Felice N van Erning, et al.
International Journal of Cancer|July 9, 2020
Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life dataPatricia A H Hamers, Marloes A G Elferink, Rebecca K Stellato, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2023
Impact of colorectal cancer screening on survival after metachronous metastasisPatricia A H Hamers, Geraldine R Vink, Marloes A G Elferink, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2024
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 monthsIngrid A Franken, Frederieke H van der Baan, Geraldine R Vink, et al.
International Journal of Cancer|August 20, 2019
Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world dataGabrielle Jongeneel, Thomas Klausch, Felice N van Erning, et al.
Journal of Geriatric Oncology|September 4, 2019
Development of a self-reported version of the G8 screening toolInez Charlotte van Walree, Ariel M Vondeling, Geraldine R Vink, et al.
Journal of Clinical Pathology|October 22, 2021
Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practiceElisabeth M P Steeghs, Geraldine R Vink, Marloes A G Elferink, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 20, 2021
Survival of surgical and non-surgical older patients with non-metastatic colorectal cancer: A population-based study in the NetherlandsEllen van der Vlies, Lisette M Vernooij, Felice N van Erning, et al.
Clinical Colorectal Cancer|April 27, 2022
Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)Patricia A H Hamers, Geraldine R Vink, Marloes A G Elferink, et al.
International Journal of Cancer|January 18, 2021
Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort studyGabrielle Jongeneel, Marjolein J E Greuter, Felice N van Erning, et al.
Pageof 7